Merck & Co. Inc (6MK DU) stock market data APIs
€126.5613
-0.13(-0.1%)
as of October 7, 2026
Try our APIs with
free plan!
Merck & Co. Inc Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for 6MK.DU.
Prev. Close
126.5613
Open
126.4332
High
126.7853
Low
126.0406
52 wk Range
69.0471-132.22
Market Cap
162 424 M
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Merck & Co. Inc data using free add-ons & libraries
Get Merck & Co. Inc Fundamental Data
Merck & Co. Inc Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Merck & Co. Inc News
New
Is Halozyme’s EU Injunction on Subcutaneous Keytruda Reshaping the Investment Case For Merck (MRK)?
In late September 2026, a Dutch court ruled in favor of Halozyme Therapeutics, issuing an injunction that halts manufacture and sale of Merck's subcutaneous Keytruda in eight European countries follow...
Sector Update: Healthcare Stocks Rise Late Afternoon
Healthcare stocks rose late Wednesday afternoon, with the NYSE Healthcare Index adding 1.2% and the PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscrip...
Sector Update: Healthcare Stocks Rise in Afternoon Trading
Healthcare stocks rose Wednesday afternoon, with the NYSE Healthcare Index adding 1.6% and the State PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Can Reblozyl Power Bristol Myers' Top-Line Growth Going Forward?
Bristol Myers BMY is banking on key drugs like Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi and Opdualag to drive top-line growth amid a significant decline in legacy drug sales. These key drugs are p...
Get Merck & Co. Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.